Humacyte

logo-cropped.jpgHumacyte is a vascular tissue engineering company pioneering the production of replacement blood vessels on demand with a patient’s own cells. Humacyte’s patented technology will focus specifically on producing small diameter grafts for patients suffering from coronary artery disease (CAD) or peripheral artery disease (PAD). Founder and former Duke bioengineering professor Laura Niklason is conducting preclinical tests now and hopes to enter clinical trials within the next few years. Humacyte is actively working to bridge its technology into the human market. URL: http://www.joeytamboli.com/humacyte/index.html